Erdheim-Chester disease

European Journal of Internal Medicine

Volumn 26, Issue 4, 2015, Pages 223-229

  Campochiaro, Corrado ^a   Tomelleri, Alessandro ^a   Cavalli, Giulio ^a   Berti, Alvise ^a   Dagna, Lorenzo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

BRAF gene; Diagnosis; Erdheim Chester disease; Histiocytosis; Treatment; Vemurafenib

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; CHLORDANE; INFLIXIMAB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN S 100; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; T6 ANTIGEN; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIABETES INSIPIDUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDOCRINE DISEASE; ENZYME ACTIVATION; ERDHEIM CHESTER DISEASE; FOLLOW UP; HISTIOCYTE; HUMAN; KIDNEY DISEASE; LUNG DISEASE; MANAGED CARE; MUSCULOSKELETAL DISEASE; ORBIT DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROGNOSIS; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL DISEASE; REVIEW; SKIN MANIFESTATION; ANTAGONISTS AND INHIBITORS; BIOPSY; DIFFERENTIAL DIAGNOSIS; ERDHEIM-CHESTER DISEASE; FEMALE; GENETICS; MALE; MUTATION; PATHOLOGY; SEX RATIO;

BIOPSY; DIAGNOSIS, DIFFERENTIAL; ERDHEIM-CHESTER DISEASE; FEMALE; HUMANS; INDOLES; INTERFERON-ALPHA; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SEX RATIO; SULFONAMIDES;

EID: 84928826133     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.03.004     Document Type: Review

References (72)

1. C. Veyssier-Belot, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases Medicine 75 3 1996 157 169
2. J. Haroche, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review Medicine 83 6 2004 371 392
3. Cavalli, G., et al., The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 72(10): p. 1691-5
4. Cavalli, G., et al., Diagnosing Erdheim-Chester disease. Ann Rheum Dis. 72(7): p. e19.
5. Jeon, I.S., S.S. Lee, and M.K. Lee, Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer. 55(4): p. 745-7
6. T.A. Tran, et al. Erdheim-Chester disease in childhood: a challenging diagnosis and treatment J Pediatr Hematol Oncol 31 10 2009 782 786
7. A. Stoppacciaro, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis Arthritis Rheum 54 12 2006 4018 4022
8. Dagna, L., et al., Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford). 49(6): p. 1203-6
9. Arnaud, L., et al., Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 117(10): p. 2783-90
10. Aouba, A., et al., Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 116(20): p. 4070-6
11. Dagna, L., et al., Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 30(28): p. e286-90
12. Ferrero, E., et al., TNF-alpha in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology (Oxford). 53(1): p. 198-200
13. Emile, J.F., et al., BRAF mutations in Erdheim-Chester disease. J Clin Oncol. 31(3): p. 398
14. Cangi, M.G., et al., BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis.
15. J.S. Sebolt-Leopold, and R. Herrera Targeting the mitogen-activated protein kinase cascade to treat cancer Nat Rev Cancer 4 12 2004 937 947
16. Y. Li, M. Nakamura, and K. Kakudo Targeting of the BRAF gene in papillary thyroid carcinoma (review) Oncol Rep 22 4 2009 671 681
17. Wellbrock, C. and A. Hurlstone, BRAF as therapeutic target in melanoma. Biochem Pharmacol. 80(5): p. 561-7
18. Tiacci, E., et al., BRAF mutations in hairy-cell leukemia. N Engl J Med. 364(24): p. 2305-15.
19. Cavalli, G., et al., Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease. Front Immunol. 5: p. 281
20. Chapman, P.B., et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364(26): p. 2507-16
21. Hauschild, A., et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380(9839): p. 358-65.
22. Haroche, J., et al., Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 121(9): p. 1495-500
23. Haroche, J., et al., Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol
24. Haroche, J., et al., Erdheim-Chester disease. Rheum Dis Clin North Am. 39(2): p. 299-311
25. Diamond, E.L., et al., Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 124(4): p. 483-92
26. J. Haroche, et al. Erdheim-Chester disease Presse Med 36 11 Pt 2 2007 1663 1668
27. Wilejto, M. and O. Abla, Langerhans cell histiocytosis and Erdheim-Chester disease. Curr Opin Rheumatol. 24(1): p. 90-6
28. L.W. Bancroft, and T.H. Berquist Erdheim-Chester disease: radiographic findings in five patients Skeletal Radiol 27 3 1998 127 132
29. E. Dion, et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement Radiology 238 2 2006 632 639
30. Balink, H., et al., Scintigraphic diagnosis of Erdheim-Chester disease. J Clin Oncol. 29(16): p. e470-2
31. Della Torre, E., et al., Erdheim-Chester disease: imaging-guided therapeutic approach. Clin Nucl Med. 36(8): p. 704-6.
32. Arnaud, L., et al., CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 117(10): p. 2778-82
33. H. Globerman, et al. A xanthogranulomatous histiocytosis in a child presenting with short stature Am J Pediatr Hematol Oncol 13 1 1991 42 46
34. E. Pautas, et al. Cerebral Erdheim-Chester disease: report of two cases with progressive cerebellar syndrome with dentate abnormalities on magnetic resonance imaging J Neurol Neurosurg Psychiatry 65 4 1998 597 599
35. R. Caputo, et al. Unusual variants of non-Langerhans cell histiocytoses J Am Acad Dermatol 57 6 2007 1031 1045
36. Pan, A., et al., Unusual manifestation of Erdheim-Chester disease. BMC Gastroenterol. 11: p. 77
37. Z.A. Karcioglu, et al. Orbital xanthogranuloma: clinical and morphologic features in eight patients Ophthal Plast Reconstr Surg 19 5 2003 372 381
38. M.E. Khamseh, et al. Erdheim-Chester syndrome, presenting as hypogonadotropic hypogonadism and diabetes insipidus J Endocrinol Invest 25 8 2002 727 729
39. N.A. Tritos, S. Weinrib, and T.B. Kaye Endocrine manifestations of Erdheim-Chester disease (a distinct form of histiocytosis) J Intern Med 244 6 1998 529 535
40. J. Haroche, et al. Bilateral adrenal infiltration in Erdheim-Chester disease Report of seven cases and literature review. J Clin Endocrinol Metab 92 6 2007 2007 2012
41. W.L. Rush, et al. Pulmonary pathology of Erdheim-Chester disease Mod Pathol 13 7 2000 747 754
42. M. Kambouchner, et al. Erdheim-Chester disease with prominent pulmonary involvement associated with eosinophilic granuloma of mandibular bone Histopathology 30 4 1997 353 358
43. A. Madroszyk, et al. Diffuse interstitial pneumonia revealing Erdheim-Chester's disease Rev Mal Respir 11 3 1994 304 307
44. F.J. Palmer, and N.J. Talley Erdheim-Chester disease with bilateral exophthalmus and liver cell adenoma Australas Radiol 28 4 1984 305 310
45. Arnaud, L., et al., Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum. 62(11): p. 3504-12.
46. A. Berti, M. Ferrarini, E. Ferrero, and L. Dagna Cardiovascular manifestations of Erdheim-Chester disease Clin Exp Rheumatol 2015 Feb 18 [epub ahead of print, PMID 25738753].
47. A.J. Egan, et al. Erdheim-Chester disease: clinical, radiologic, and histopathologic findings in five patients with interstitial lung disease Am J Surg Pathol 23 1 1999 17 26
48. Alharthi, M.S., et al., Multimodality imaging showing complete cardiovascular involvement by Erdheim-Chester disease. Eur J Echocardiogr. 11(7): p. E25.
49. J. Haroche, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients Circulation 119 25 2009 e597 e598
50. A. Vaglio, et al. Pericarditis heralding Erdheim-Chester disease Circulation 118 14 2008 e511 e512
51. J. Serratrice, et al. "Coated aorta": a new sign of Erdheim-Chester disease J Rheumatol 27 6 2000 1550 1553
52. M.G. Fink, et al. Erdheim-Chester disease Case report with autopsy findings. Arch Pathol Lab Med 115 6 1991 619 623
53. A.G. Loeffler, and V.A. Memoli Myocardial involvement in Erdheim-Chester disease Arch Pathol Lab Med 128 6 2004 682 685
54. Lauretta, L., et al., [Cardiovascular involvement in Erdheim-Chester syndrome: clinical and therapeutic implications]. Recenti Prog Med. 104(12): p. 637-42
55. M.C. Jendro, et al. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil Clin Rheumatol 23 1 2004 52 56
56. Broccoli, A., et al., Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int. 32(7): p. 2209-13
57. N. Boissel, B. Wechsler, and V. Leblond Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation Ann Intern Med 135 9 2001 844 845
58. S.C. Bourke, A.G. Nicholson, and G.J. Gibson Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone Thorax 58 11 2003 1004 1005
59. Z. Wu, et al. A case of Erdheim-Chester disease with bilateral orbital involvement Yan Ke Xue Bao 17 3 2001 163 167
60. N. Gaspar, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement Haematologica 91 8 2006 1121 1125
61. F. Braiteh, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha Blood 106 9 2005 2992 2994
62. B. Esmaeli, et al. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease Am J Ophthalmol 132 6 2001 945 947
63. Suzuki, H.I., et al., Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res. 34(1): p. e21-4
64. J. Haroche, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients Arthritis Rheum 54 10 2006 3330 3336
65. Aubert, O., et al., Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine. 80(2): p. 206-7.
66. Tran, T.A., et al., Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum. 63(12): p. 4031-2.
67. Killu, A.M., J.J. Liang, and A.S. Jaffe, Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol. 167(5): p. e115-7.
68. Dietrich, S., et al., Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 31(19): p. e300-3.
69. Dietrich, S., et al., BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 366(21): p. 2038-40.
70. L. Arnaud, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease Arthritis Rheum 60 10 2009 3128 3138
71. E.L. Diamond, et al. Detection of an NRAS mutation in Erdheim-Chester disease Blood 122 6 2013 1089 1091
72. J.F. Emile, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease Blood 124 19 2014 3016 3019